Interesting interview with Pr. Michael Hofman about TheraP Trial Design Evaluating 177Lu‐PSMA‐617 Theranostic Treatment vs Cabazitaxel in Progressive Metastatic Castration‐Resistant Prostate Cancer, where results are expected in 2020.

See the interview >>